Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.

Trial Details

NCT ID
NCT06458712
Phase
PHASE1
Sponsor
Duke Street Bio Ltd
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • DSB2455
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327
  • Bordeaux, France|44.84124,-0.58046
  • Reims, France|49.26526,4.02853

Key Eligibility Criteria

  • The participant (or legally acceptable representative, if applicable) provides written informed consent for the study.
  • Aged ≥18 years of age on the day of signing the informed consent.
  • Has measurable disease per RECIST v1.1, or non-measurable disease as defined in the protocol.
  • ECOG performance status of 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →